Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioblastoma | 179 | 2024 | 3482 | 15.450 |
Why?
|
Brain Neoplasms | 239 | 2024 | 9031 | 11.440 |
Why?
|
Glioma | 102 | 2024 | 3455 | 7.760 |
Why?
|
Dacarbazine | 50 | 2023 | 559 | 4.860 |
Why?
|
Neoplasm Recurrence, Local | 87 | 2023 | 9277 | 4.250 |
Why?
|
Angiogenesis Inhibitors | 38 | 2020 | 2047 | 3.850 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 80 | 2022 | 11740 | 3.290 |
Why?
|
Immunotherapy | 39 | 2024 | 4650 | 2.970 |
Why?
|
Central Nervous System Neoplasms | 16 | 2022 | 916 | 2.770 |
Why?
|
Antineoplastic Agents | 55 | 2023 | 13637 | 2.640 |
Why?
|
Cancer Vaccines | 19 | 2024 | 1050 | 2.580 |
Why?
|
Astrocytoma | 17 | 2015 | 775 | 1.910 |
Why?
|
Antineoplastic Agents, Alkylating | 27 | 2024 | 617 | 1.770 |
Why?
|
Antibodies, Monoclonal | 35 | 2022 | 9179 | 1.710 |
Why?
|
Snake Venoms | 6 | 2015 | 40 | 1.710 |
Why?
|
Meningioma | 15 | 2022 | 1218 | 1.690 |
Why?
|
Meningeal Neoplasms | 16 | 2022 | 1248 | 1.580 |
Why?
|
Camptothecin | 17 | 2015 | 590 | 1.450 |
Why?
|
Oligodendroglioma | 13 | 2020 | 279 | 1.440 |
Why?
|
DNA Modification Methylases | 11 | 2023 | 210 | 1.400 |
Why?
|
DNA Repair Enzymes | 12 | 2023 | 346 | 1.360 |
Why?
|
Quinazolines | 14 | 2015 | 1371 | 1.320 |
Why?
|
Isocitrate Dehydrogenase | 14 | 2024 | 938 | 1.300 |
Why?
|
Blood-Brain Barrier | 7 | 2024 | 1027 | 1.220 |
Why?
|
Tenascin | 7 | 2008 | 62 | 1.190 |
Why?
|
Maximum Tolerated Dose | 25 | 2019 | 883 | 1.140 |
Why?
|
Dexamethasone | 6 | 2022 | 1947 | 1.090 |
Why?
|
Radioimmunotherapy | 9 | 2008 | 91 | 1.080 |
Why?
|
Combined Modality Therapy | 38 | 2022 | 8529 | 1.060 |
Why?
|
Disease-Free Survival | 43 | 2023 | 6814 | 1.050 |
Why?
|
Clinical Trials as Topic | 31 | 2022 | 8000 | 1.050 |
Why?
|
Salvage Therapy | 13 | 2018 | 1264 | 1.030 |
Why?
|
Nervous System Neoplasms | 2 | 2015 | 91 | 1.000 |
Why?
|
Humans | 373 | 2024 | 761423 | 0.960 |
Why?
|
Treatment Outcome | 86 | 2024 | 64651 | 0.920 |
Why?
|
Sirolimus | 6 | 2012 | 1533 | 0.890 |
Why?
|
Immunoconjugates | 6 | 2019 | 954 | 0.890 |
Why?
|
Oncolytic Viruses | 5 | 2023 | 344 | 0.880 |
Why?
|
Sonication | 2 | 2020 | 79 | 0.840 |
Why?
|
Medical Oncology | 6 | 2022 | 2321 | 0.820 |
Why?
|
Immunomodulation | 2 | 2017 | 548 | 0.810 |
Why?
|
Tumor Suppressor Proteins | 12 | 2023 | 2803 | 0.810 |
Why?
|
Adult | 173 | 2024 | 221148 | 0.810 |
Why?
|
Middle Aged | 179 | 2024 | 220826 | 0.800 |
Why?
|
Neovascularization, Pathologic | 9 | 2017 | 2644 | 0.770 |
Why?
|
Brain Edema | 3 | 2020 | 604 | 0.770 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 6 | 2013 | 664 | 0.760 |
Why?
|
Aged | 139 | 2024 | 169235 | 0.760 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 2019 | 3490 | 0.760 |
Why?
|
Indoles | 5 | 2020 | 1832 | 0.750 |
Why?
|
Protein Kinase Inhibitors | 12 | 2023 | 5665 | 0.740 |
Why?
|
Carboplatin | 6 | 2019 | 794 | 0.740 |
Why?
|
Survival Rate | 43 | 2024 | 12720 | 0.730 |
Why?
|
Magnetic Resonance Imaging | 50 | 2024 | 36423 | 0.720 |
Why?
|
Succinimides | 1 | 2020 | 81 | 0.710 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2020 | 70 | 0.700 |
Why?
|
Hydroxyurea | 7 | 2012 | 284 | 0.690 |
Why?
|
Integrins | 5 | 2012 | 834 | 0.690 |
Why?
|
Tumor Microenvironment | 15 | 2024 | 3874 | 0.690 |
Why?
|
Male | 194 | 2024 | 360736 | 0.660 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 117 | 0.660 |
Why?
|
Antigens, Neoplasm | 9 | 2024 | 1994 | 0.660 |
Why?
|
Prognosis | 50 | 2024 | 29620 | 0.650 |
Why?
|
Female | 201 | 2024 | 392581 | 0.650 |
Why?
|
Antigen Presentation | 2 | 2023 | 1253 | 0.640 |
Why?
|
Kaplan-Meier Estimate | 22 | 2020 | 6479 | 0.600 |
Why?
|
Neurology | 2 | 2015 | 780 | 0.580 |
Why?
|
Angiopoietins | 1 | 2017 | 85 | 0.580 |
Why?
|
Pyrimidines | 10 | 2013 | 3027 | 0.570 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2011 | 678 | 0.540 |
Why?
|
Brain Stem Neoplasms | 3 | 2016 | 190 | 0.540 |
Why?
|
Microbubbles | 3 | 2024 | 135 | 0.530 |
Why?
|
Vaccines, Subunit | 7 | 2022 | 161 | 0.520 |
Why?
|
Drug Delivery Systems | 10 | 2024 | 2225 | 0.510 |
Why?
|
Melanoma | 7 | 2023 | 5709 | 0.500 |
Why?
|
Oncolytic Virotherapy | 5 | 2023 | 516 | 0.490 |
Why?
|
Drug Administration Schedule | 18 | 2015 | 4852 | 0.490 |
Why?
|
Pituitary Neoplasms | 6 | 2023 | 1324 | 0.490 |
Why?
|
Iodine Radioisotopes | 4 | 2008 | 1033 | 0.480 |
Why?
|
Oligopeptides | 2 | 2011 | 1187 | 0.460 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2015 | 1784 | 0.450 |
Why?
|
Disease Progression | 31 | 2023 | 13502 | 0.450 |
Why?
|
Herpesvirus 1, Human | 5 | 2023 | 753 | 0.450 |
Why?
|
Survival Analysis | 32 | 2023 | 10089 | 0.440 |
Why?
|
Pyridines | 8 | 2018 | 2875 | 0.440 |
Why?
|
Neoplasms | 15 | 2021 | 22164 | 0.440 |
Why?
|
Purines | 3 | 2012 | 605 | 0.430 |
Why?
|
Encephalitis | 1 | 2017 | 438 | 0.430 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2019 | 546 | 0.420 |
Why?
|
Etoposide | 4 | 2010 | 634 | 0.420 |
Why?
|
Dendritic Cells | 5 | 2022 | 2746 | 0.420 |
Why?
|
Molecular Targeted Therapy | 4 | 2019 | 2811 | 0.410 |
Why?
|
Anticonvulsants | 7 | 2016 | 1906 | 0.400 |
Why?
|
Piperazines | 8 | 2012 | 2523 | 0.400 |
Why?
|
Anilides | 4 | 2018 | 411 | 0.390 |
Why?
|
Benzamides | 8 | 2012 | 1370 | 0.390 |
Why?
|
T-Lymphocytes | 11 | 2024 | 10194 | 0.390 |
Why?
|
Dose-Response Relationship, Drug | 18 | 2020 | 10766 | 0.380 |
Why?
|
Adrenal Cortex Hormones | 6 | 2022 | 1876 | 0.380 |
Why?
|
Mutation | 27 | 2024 | 30045 | 0.370 |
Why?
|
Genetic Heterogeneity | 1 | 2015 | 732 | 0.370 |
Why?
|
Young Adult | 43 | 2024 | 59207 | 0.370 |
Why?
|
Sulfonamides | 3 | 2013 | 1975 | 0.370 |
Why?
|
Fibronectins | 1 | 2014 | 723 | 0.370 |
Why?
|
Tissue Distribution | 9 | 2019 | 2265 | 0.370 |
Why?
|
Striae Distensae | 1 | 2010 | 7 | 0.360 |
Why?
|
Follow-Up Studies | 33 | 2024 | 39117 | 0.360 |
Why?
|
Nervous System Diseases | 2 | 2021 | 1666 | 0.360 |
Why?
|
Rare Diseases | 1 | 2016 | 621 | 0.350 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2010 | 114 | 0.340 |
Why?
|
Tumor Burden | 9 | 2018 | 1890 | 0.330 |
Why?
|
Medulloblastoma | 5 | 2008 | 678 | 0.330 |
Why?
|
Cerebellar Neoplasms | 5 | 2015 | 586 | 0.320 |
Why?
|
Carmustine | 7 | 2014 | 138 | 0.320 |
Why?
|
Kynurenine | 2 | 2020 | 141 | 0.320 |
Why?
|
Animals | 50 | 2024 | 168441 | 0.320 |
Why?
|
Positron-Emission Tomography | 11 | 2024 | 6485 | 0.320 |
Why?
|
Lymphopenia | 4 | 2012 | 280 | 0.320 |
Why?
|
Ulcer | 1 | 2010 | 204 | 0.320 |
Why?
|
Immunologic Factors | 3 | 2022 | 1588 | 0.310 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 5 | 2021 | 1090 | 0.310 |
Why?
|
Craniopharyngioma | 2 | 2023 | 277 | 0.310 |
Why?
|
DNA Methylation | 9 | 2023 | 4391 | 0.300 |
Why?
|
Thrombocytopenia | 3 | 2015 | 1179 | 0.300 |
Why?
|
Health Behavior | 3 | 2011 | 2641 | 0.280 |
Why?
|
Molecular Biology | 1 | 2011 | 578 | 0.280 |
Why?
|
Exercise | 4 | 2011 | 5884 | 0.280 |
Why?
|
Exotoxins | 5 | 2008 | 121 | 0.270 |
Why?
|
Phthalazines | 1 | 2009 | 383 | 0.270 |
Why?
|
Peptides, Cyclic | 1 | 2008 | 392 | 0.270 |
Why?
|
Interferon-gamma | 4 | 2023 | 3159 | 0.270 |
Why?
|
Recurrence | 10 | 2015 | 8469 | 0.270 |
Why?
|
Neoplasm Staging | 18 | 2019 | 11106 | 0.270 |
Why?
|
Retrospective Studies | 45 | 2024 | 80582 | 0.260 |
Why?
|
Psychological Theory | 1 | 2007 | 175 | 0.260 |
Why?
|
Aged, 80 and over | 32 | 2022 | 58956 | 0.260 |
Why?
|
Pyrroles | 2 | 2011 | 1125 | 0.260 |
Why?
|
Chromosome Aberrations | 4 | 2019 | 1771 | 0.250 |
Why?
|
Thalamus | 2 | 2004 | 1044 | 0.250 |
Why?
|
Mice | 29 | 2024 | 81509 | 0.250 |
Why?
|
Guanine | 6 | 2009 | 279 | 0.250 |
Why?
|
Kluver-Bucy Syndrome | 1 | 2004 | 9 | 0.240 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2009 | 621 | 0.240 |
Why?
|
Clinical Trials, Phase II as Topic | 5 | 2015 | 629 | 0.240 |
Why?
|
Rhabdoid Tumor | 2 | 2017 | 210 | 0.230 |
Why?
|
Contrast Media | 6 | 2019 | 5311 | 0.230 |
Why?
|
Intention | 1 | 2007 | 347 | 0.230 |
Why?
|
Holography | 1 | 2024 | 80 | 0.230 |
Why?
|
Blood Vessels | 2 | 2008 | 1113 | 0.220 |
Why?
|
Nucleic Acid Hybridization | 3 | 2000 | 1306 | 0.220 |
Why?
|
Cell Line, Tumor | 14 | 2020 | 16979 | 0.220 |
Why?
|
Tuberous Sclerosis | 1 | 2011 | 1030 | 0.220 |
Why?
|
Respiration | 1 | 2010 | 1657 | 0.220 |
Why?
|
STAT Transcription Factors | 1 | 2023 | 188 | 0.210 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 4 | 2013 | 83 | 0.210 |
Why?
|
Medulla Oblongata | 1 | 2004 | 248 | 0.210 |
Why?
|
ACTH-Secreting Pituitary Adenoma | 1 | 2023 | 63 | 0.210 |
Why?
|
Promoter Regions, Genetic | 7 | 2021 | 5789 | 0.210 |
Why?
|
Janus Kinases | 1 | 2023 | 248 | 0.210 |
Why?
|
Karnofsky Performance Status | 5 | 2019 | 166 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2024 | 857 | 0.200 |
Why?
|
Drug Interactions | 2 | 2020 | 1414 | 0.200 |
Why?
|
Cell-Penetrating Peptides | 1 | 2022 | 49 | 0.200 |
Why?
|
Drug Therapy, Combination | 5 | 2017 | 6309 | 0.200 |
Why?
|
Peptide Fragments | 1 | 2014 | 5115 | 0.200 |
Why?
|
Vaccination | 3 | 2021 | 3381 | 0.200 |
Why?
|
Signal Transduction | 12 | 2023 | 23441 | 0.190 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 2019 | 0.190 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2022 | 2549 | 0.190 |
Why?
|
Enzyme Inhibitors | 5 | 2012 | 3712 | 0.190 |
Why?
|
Transforming Growth Factor alpha | 3 | 2008 | 135 | 0.190 |
Why?
|
Phosphoramide Mustards | 1 | 2021 | 18 | 0.190 |
Why?
|
Recombinant Fusion Proteins | 6 | 2020 | 3734 | 0.190 |
Why?
|
Practice Guidelines as Topic | 5 | 2021 | 7389 | 0.190 |
Why?
|
Ki-67 Antigen | 2 | 2022 | 629 | 0.190 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2021 | 84 | 0.180 |
Why?
|
Administration, Oral | 5 | 2011 | 4016 | 0.180 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2020 | 638 | 0.180 |
Why?
|
Interleukin-12 | 2 | 2022 | 583 | 0.180 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 306 | 0.180 |
Why?
|
Chromosome Deletion | 3 | 2020 | 1387 | 0.180 |
Why?
|
Neoplasm Invasiveness | 5 | 2018 | 3589 | 0.170 |
Why?
|
Nitroimidazoles | 1 | 2021 | 117 | 0.170 |
Why?
|
Gliosarcoma | 1 | 2020 | 114 | 0.170 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2018 | 3769 | 0.170 |
Why?
|
Cohort Studies | 18 | 2022 | 41446 | 0.170 |
Why?
|
Adenoma | 2 | 2023 | 2160 | 0.170 |
Why?
|
Giant Cells | 1 | 2000 | 188 | 0.170 |
Why?
|
Random Allocation | 2 | 2023 | 2394 | 0.170 |
Why?
|
Purpura | 1 | 2020 | 117 | 0.170 |
Why?
|
Fatigue | 4 | 2016 | 1551 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 11 | 2021 | 5305 | 0.170 |
Why?
|
DNA Mutational Analysis | 7 | 2021 | 4110 | 0.170 |
Why?
|
Disease Models, Animal | 8 | 2021 | 18247 | 0.170 |
Why?
|
Rats, Inbred F344 | 1 | 2020 | 826 | 0.160 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2020 | 242 | 0.160 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2020 | 350 | 0.160 |
Why?
|
Genes, myc | 1 | 2000 | 390 | 0.160 |
Why?
|
Maytansine | 1 | 2019 | 86 | 0.160 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2024 | 455 | 0.160 |
Why?
|
Adipose Tissue, Brown | 1 | 2024 | 764 | 0.150 |
Why?
|
Prodrugs | 1 | 2020 | 261 | 0.150 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2019 | 126 | 0.150 |
Why?
|
Tryptophan | 1 | 2020 | 482 | 0.150 |
Why?
|
Astatine | 2 | 2007 | 10 | 0.150 |
Why?
|
Gyrus Cinguli | 1 | 2004 | 1115 | 0.150 |
Why?
|
Algorithms | 9 | 2020 | 14026 | 0.150 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 1999 | 375 | 0.150 |
Why?
|
Pyridazines | 1 | 2019 | 202 | 0.150 |
Why?
|
Decanoic Acids | 2 | 2009 | 68 | 0.150 |
Why?
|
Protein Phosphatase 1 | 1 | 2018 | 134 | 0.150 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 1998 | 310 | 0.140 |
Why?
|
Drug Evaluation, Preclinical | 4 | 2011 | 1334 | 0.140 |
Why?
|
Pyrazoles | 2 | 2023 | 2007 | 0.140 |
Why?
|
Ependymoma | 2 | 2005 | 320 | 0.140 |
Why?
|
Pilot Projects | 6 | 2020 | 8633 | 0.140 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2054 | 0.140 |
Why?
|
Neurosurgical Procedures | 5 | 2019 | 2072 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2020 | 10203 | 0.140 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2019 | 220 | 0.140 |
Why?
|
Area Under Curve | 5 | 2016 | 1638 | 0.140 |
Why?
|
Glutarates | 1 | 2018 | 243 | 0.140 |
Why?
|
Heart | 1 | 2010 | 4405 | 0.140 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2023 | 782 | 0.140 |
Why?
|
Apyrase | 1 | 2019 | 373 | 0.130 |
Why?
|
Cranial Irradiation | 1 | 2019 | 390 | 0.130 |
Why?
|
Amygdala | 1 | 2004 | 1353 | 0.130 |
Why?
|
Injections, Intralesional | 2 | 2008 | 277 | 0.130 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2020 | 1784 | 0.130 |
Why?
|
Oncogene Proteins v-erbB | 1 | 2015 | 17 | 0.130 |
Why?
|
Adolescent | 27 | 2024 | 88313 | 0.130 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2021 | 8999 | 0.130 |
Why?
|
Gadolinium DTPA | 2 | 2011 | 823 | 0.130 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2015 | 3077 | 0.130 |
Why?
|
Neoplasm, Residual | 2 | 2018 | 1008 | 0.130 |
Why?
|
Antigens, Viral | 1 | 2020 | 988 | 0.130 |
Why?
|
Phantoms, Imaging | 1 | 2024 | 2525 | 0.130 |
Why?
|
Rats | 3 | 2024 | 23742 | 0.130 |
Why?
|
Morpholines | 1 | 2019 | 581 | 0.130 |
Why?
|
Polyesters | 2 | 2009 | 373 | 0.130 |
Why?
|
Portraits as Topic | 1 | 2015 | 32 | 0.130 |
Why?
|
Ganglioglioma | 1 | 2015 | 36 | 0.130 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2015 | 326 | 0.130 |
Why?
|
Tissue Extracts | 1 | 2015 | 141 | 0.130 |
Why?
|
Piracetam | 1 | 2016 | 88 | 0.130 |
Why?
|
Chemokine CCL3 | 1 | 2015 | 84 | 0.120 |
Why?
|
Immunotoxins | 4 | 2008 | 175 | 0.120 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 1998 | 2510 | 0.120 |
Why?
|
Proportional Hazards Models | 11 | 2023 | 12456 | 0.120 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2018 | 431 | 0.120 |
Why?
|
Lymphoma | 3 | 2013 | 1901 | 0.120 |
Why?
|
Aminopyridines | 1 | 2019 | 573 | 0.120 |
Why?
|
Epilepsy | 2 | 2024 | 3290 | 0.120 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2020 | 3602 | 0.120 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2020 | 611 | 0.120 |
Why?
|
Biological Transport | 1 | 2019 | 2092 | 0.120 |
Why?
|
Adenoma, Oxyphilic | 1 | 2016 | 148 | 0.120 |
Why?
|
Muscle, Skeletal | 1 | 2010 | 4946 | 0.120 |
Why?
|
Polymerase Chain Reaction | 4 | 2016 | 6086 | 0.120 |
Why?
|
Infratentorial Neoplasms | 1 | 2015 | 98 | 0.120 |
Why?
|
Tetanus Toxoid | 1 | 2015 | 193 | 0.120 |
Why?
|
Central Nervous System | 1 | 2022 | 1337 | 0.120 |
Why?
|
Gene Expression | 2 | 2018 | 7584 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2020 | 962 | 0.120 |
Why?
|
Hepatocyte Growth Factor | 2 | 2018 | 270 | 0.120 |
Why?
|
Brachytherapy | 2 | 2015 | 1223 | 0.120 |
Why?
|
Immunohistochemistry | 9 | 2018 | 11073 | 0.120 |
Why?
|
Glucuronosyltransferase | 1 | 2014 | 132 | 0.120 |
Why?
|
Gene Amplification | 1 | 2019 | 1088 | 0.110 |
Why?
|
Tyrosine | 1 | 2018 | 1440 | 0.110 |
Why?
|
Radiopharmaceuticals | 7 | 2010 | 2651 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2020 | 803 | 0.110 |
Why?
|
Patient Selection | 4 | 2020 | 4244 | 0.110 |
Why?
|
Philadelphia Chromosome | 1 | 1994 | 117 | 0.110 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2013 | 748 | 0.110 |
Why?
|
World Health Organization | 4 | 2022 | 1316 | 0.110 |
Why?
|
Diagnostic Imaging | 4 | 2014 | 3530 | 0.110 |
Why?
|
DNA, Neoplasm | 2 | 2004 | 1745 | 0.110 |
Why?
|
Receptors, CXCR4 | 1 | 2018 | 727 | 0.110 |
Why?
|
Receptors, Cell Surface | 3 | 2021 | 2821 | 0.110 |
Why?
|
Chromosome Mapping | 3 | 1998 | 4638 | 0.110 |
Why?
|
Imidazoles | 1 | 2019 | 1180 | 0.110 |
Why?
|
Patients | 1 | 2020 | 906 | 0.110 |
Why?
|
Antigen-Presenting Cells | 1 | 2017 | 965 | 0.110 |
Why?
|
Mibefradil | 1 | 2012 | 5 | 0.110 |
Why?
|
Rats, Sprague-Dawley | 2 | 2024 | 8179 | 0.110 |
Why?
|
Double-Blind Method | 4 | 2020 | 12330 | 0.110 |
Why?
|
Valproic Acid | 1 | 2016 | 443 | 0.110 |
Why?
|
Treatment Failure | 4 | 2017 | 2642 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2020 | 8545 | 0.110 |
Why?
|
Skin Neoplasms | 3 | 2018 | 5819 | 0.110 |
Why?
|
Time Factors | 13 | 2019 | 39975 | 0.110 |
Why?
|
Lymph Nodes | 2 | 2022 | 3466 | 0.100 |
Why?
|
Somatostatin | 1 | 2014 | 447 | 0.100 |
Why?
|
Stromal Cells | 1 | 2018 | 1330 | 0.100 |
Why?
|
Benzenesulfonates | 2 | 2010 | 166 | 0.100 |
Why?
|
Attitude to Health | 2 | 2019 | 2025 | 0.100 |
Why?
|
Teratoma | 1 | 2015 | 404 | 0.100 |
Why?
|
Prospective Studies | 12 | 2020 | 54415 | 0.100 |
Why?
|
Neoadjuvant Therapy | 3 | 2019 | 2826 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2019 | 3514 | 0.100 |
Why?
|
Consensus | 4 | 2023 | 3122 | 0.100 |
Why?
|
Confidence Intervals | 3 | 2014 | 2927 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 481 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2023 | 4575 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2018 | 570 | 0.100 |
Why?
|
Postoperative Care | 1 | 2018 | 1471 | 0.100 |
Why?
|
Immunity | 2 | 2015 | 997 | 0.100 |
Why?
|
Endpoint Determination | 1 | 2014 | 590 | 0.100 |
Why?
|
Cell Movement | 4 | 2018 | 5203 | 0.100 |
Why?
|
Quality of Life | 6 | 2019 | 13361 | 0.100 |
Why?
|
Niacinamide | 2 | 2010 | 413 | 0.090 |
Why?
|
Interleukin-13 | 3 | 2010 | 390 | 0.090 |
Why?
|
Magnetic Resonance Angiography | 2 | 2008 | 1432 | 0.090 |
Why?
|
Antineoplastic Protocols | 1 | 2011 | 48 | 0.090 |
Why?
|
Tablets | 1 | 2011 | 147 | 0.090 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 1991 | 22 | 0.090 |
Why?
|
Indazoles | 1 | 2013 | 304 | 0.090 |
Why?
|
Optic Nerve Glioma | 1 | 2011 | 32 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 1517 | 0.090 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2011 | 50 | 0.090 |
Why?
|
Optic Nerve Neoplasms | 1 | 2011 | 45 | 0.090 |
Why?
|
Yin-Yang | 1 | 2010 | 10 | 0.090 |
Why?
|
Cell Survival | 2 | 2018 | 5790 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 2223 | 0.090 |
Why?
|
Neutropenia | 2 | 2015 | 884 | 0.090 |
Why?
|
Research Design | 4 | 2022 | 6178 | 0.090 |
Why?
|
Spinal Cord Neoplasms | 2 | 2006 | 263 | 0.090 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 1998 | 1250 | 0.090 |
Why?
|
Adenoviridae Infections | 1 | 1991 | 93 | 0.090 |
Why?
|
Telomerase | 1 | 2015 | 745 | 0.090 |
Why?
|
Child, Preschool | 19 | 2024 | 42254 | 0.090 |
Why?
|
Piperidines | 2 | 2011 | 1656 | 0.090 |
Why?
|
Probability | 2 | 2006 | 2478 | 0.090 |
Why?
|
Phenylurea Compounds | 2 | 2010 | 529 | 0.090 |
Why?
|
Comparative Genomic Hybridization | 3 | 2016 | 473 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2022 | 2298 | 0.080 |
Why?
|
DNA Copy Number Variations | 2 | 2015 | 2020 | 0.080 |
Why?
|
History, 21st Century | 1 | 2015 | 1567 | 0.080 |
Why?
|
Lymphocyte Depletion | 1 | 2011 | 602 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 641 | 0.080 |
Why?
|
Calcium Channel Blockers | 1 | 2012 | 694 | 0.080 |
Why?
|
Diarrhea | 2 | 2015 | 1318 | 0.080 |
Why?
|
MAP Kinase Signaling System | 1 | 2016 | 1486 | 0.080 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 916 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1994 | 686 | 0.080 |
Why?
|
Brain | 10 | 2021 | 27107 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2018 | 2571 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3163 | 0.080 |
Why?
|
Immunologic Memory | 1 | 2015 | 1358 | 0.080 |
Why?
|
Antigens, CD | 1 | 2019 | 4001 | 0.080 |
Why?
|
STAT1 Transcription Factor | 2 | 2020 | 340 | 0.080 |
Why?
|
Genetic Vectors | 1 | 2018 | 3395 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1743 | 0.080 |
Why?
|
Age Factors | 5 | 2024 | 18400 | 0.080 |
Why?
|
Predictive Value of Tests | 8 | 2020 | 15262 | 0.080 |
Why?
|
Risk Assessment | 5 | 2018 | 23990 | 0.070 |
Why?
|
Mutant Proteins | 1 | 2009 | 491 | 0.070 |
Why?
|
Image Enhancement | 1 | 2018 | 2884 | 0.070 |
Why?
|
History, 20th Century | 1 | 2015 | 2769 | 0.070 |
Why?
|
Child | 20 | 2024 | 80162 | 0.070 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4248 | 0.070 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2009 | 344 | 0.070 |
Why?
|
Drug Design | 1 | 2012 | 1048 | 0.070 |
Why?
|
Vestibular Nerve | 1 | 2007 | 101 | 0.070 |
Why?
|
Attitude | 1 | 1992 | 775 | 0.070 |
Why?
|
Neoplasm Metastasis | 2 | 2009 | 4912 | 0.070 |
Why?
|
Radiometry | 3 | 2007 | 813 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2022 | 4320 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2014 | 1520 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2019 | 3600 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2006 | 882 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2863 | 0.070 |
Why?
|
Feasibility Studies | 4 | 2012 | 5246 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2022 | 3639 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2024 | 3356 | 0.070 |
Why?
|
Farnesyltranstransferase | 1 | 2006 | 71 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3249 | 0.070 |
Why?
|
Ultrasonography | 1 | 2019 | 5970 | 0.070 |
Why?
|
Abortion, Induced | 1 | 1992 | 462 | 0.070 |
Why?
|
Body Burden | 1 | 2006 | 158 | 0.060 |
Why?
|
Mice, Inbred C57BL | 6 | 2024 | 22163 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2009 | 727 | 0.060 |
Why?
|
Infusions, Intravenous | 3 | 2005 | 2218 | 0.060 |
Why?
|
Decision Making | 1 | 2019 | 3929 | 0.060 |
Why?
|
Macrophages | 2 | 2019 | 5768 | 0.060 |
Why?
|
Cell Lineage | 1 | 2014 | 2555 | 0.060 |
Why?
|
Muscle Strength | 1 | 2010 | 624 | 0.060 |
Why?
|
Catheters, Indwelling | 1 | 2008 | 426 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 1991 | 856 | 0.060 |
Why?
|
Chromosome Disorders | 2 | 1999 | 499 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4876 | 0.060 |
Why?
|
Physical Fitness | 1 | 2010 | 739 | 0.060 |
Why?
|
Biopsy | 3 | 2021 | 6766 | 0.060 |
Why?
|
Reproducibility of Results | 6 | 2023 | 20093 | 0.060 |
Why?
|
Cochlear Nerve | 1 | 2007 | 202 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4234 | 0.060 |
Why?
|
Receptor, erbB-2 | 2 | 2014 | 2557 | 0.060 |
Why?
|
Administration, Topical | 1 | 2007 | 703 | 0.060 |
Why?
|
Hydrazines | 1 | 2006 | 224 | 0.060 |
Why?
|
Sickness Impact Profile | 1 | 2006 | 299 | 0.060 |
Why?
|
Multiprotein Complexes | 1 | 2011 | 1118 | 0.060 |
Why?
|
Catheterization | 1 | 2010 | 1432 | 0.060 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 1551 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2015 | 2916 | 0.060 |
Why?
|
DNA Helicases | 2 | 2024 | 851 | 0.060 |
Why?
|
Thiazoles | 1 | 2012 | 1517 | 0.060 |
Why?
|
Paranoid Disorders | 1 | 2004 | 61 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2057 | 0.060 |
Why?
|
Drug Industry | 1 | 2011 | 788 | 0.060 |
Why?
|
Seizures | 3 | 2024 | 2957 | 0.060 |
Why?
|
Neoplasm Proteins | 3 | 2013 | 3612 | 0.060 |
Why?
|
Hematologic Neoplasms | 1 | 2016 | 1896 | 0.060 |
Why?
|
Cell Cycle | 1 | 2012 | 2932 | 0.060 |
Why?
|
Reference Values | 2 | 2014 | 4921 | 0.060 |
Why?
|
Lung Neoplasms | 3 | 2021 | 13337 | 0.060 |
Why?
|
Biological Availability | 1 | 2005 | 390 | 0.060 |
Why?
|
Polymorphism, Genetic | 1 | 2014 | 4287 | 0.060 |
Why?
|
Walking | 1 | 2011 | 1200 | 0.060 |
Why?
|
Lomustine | 2 | 2014 | 60 | 0.060 |
Why?
|
Infant | 12 | 2018 | 36205 | 0.060 |
Why?
|
Neurofibromatosis 2 | 1 | 2007 | 385 | 0.050 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2007 | 380 | 0.050 |
Why?
|
Oxygen Consumption | 1 | 2010 | 1863 | 0.050 |
Why?
|
Adenosine Triphosphatases | 1 | 2007 | 834 | 0.050 |
Why?
|
Transducers | 1 | 2024 | 241 | 0.050 |
Why?
|
Pinealoma | 1 | 2003 | 52 | 0.050 |
Why?
|
Papilloma, Choroid Plexus | 2 | 1999 | 9 | 0.050 |
Why?
|
Neuroma, Acoustic | 1 | 2007 | 459 | 0.050 |
Why?
|
Cerebral Angiography | 1 | 2008 | 1281 | 0.050 |
Why?
|
Culture | 1 | 2007 | 623 | 0.050 |
Why?
|
Bone Marrow Transplantation | 1 | 1991 | 2695 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 3244 | 0.050 |
Why?
|
Acoustics | 1 | 2024 | 242 | 0.050 |
Why?
|
Injections, Intraventricular | 3 | 2008 | 225 | 0.050 |
Why?
|
Pineal Gland | 1 | 2003 | 158 | 0.050 |
Why?
|
Cross-Priming | 1 | 2022 | 76 | 0.050 |
Why?
|
Demography | 1 | 2007 | 1648 | 0.050 |
Why?
|
Temporal Muscle | 1 | 2021 | 36 | 0.050 |
Why?
|
Genes, erbB | 1 | 2001 | 5 | 0.050 |
Why?
|
Radiosurgery | 1 | 2011 | 1342 | 0.050 |
Why?
|
Misonidazole | 1 | 2021 | 33 | 0.050 |
Why?
|
Convection | 2 | 2011 | 30 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3538 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2009 | 6231 | 0.050 |
Why?
|
Losartan | 1 | 2023 | 265 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 12970 | 0.050 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9418 | 0.050 |
Why?
|
Sex Distribution | 1 | 2006 | 2281 | 0.050 |
Why?
|
Pentamidine | 1 | 2020 | 44 | 0.050 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2007 | 781 | 0.050 |
Why?
|
Body Mass Index | 2 | 2010 | 12951 | 0.040 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1624 | 0.040 |
Why?
|
Pituitary Gland | 1 | 2023 | 635 | 0.040 |
Why?
|
Venous Thromboembolism | 2 | 2014 | 1866 | 0.040 |
Why?
|
Body Composition | 1 | 2010 | 2422 | 0.040 |
Why?
|
Mice, Nude | 3 | 2018 | 3614 | 0.040 |
Why?
|
Virus Replication | 2 | 2018 | 2435 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2021 | 161 | 0.040 |
Why?
|
Age Distribution | 1 | 2006 | 2880 | 0.040 |
Why?
|
Abnormalities, Multiple | 1 | 2007 | 1424 | 0.040 |
Why?
|
Radiation, Ionizing | 1 | 2001 | 251 | 0.040 |
Why?
|
Immunoenzyme Techniques | 2 | 2015 | 1706 | 0.040 |
Why?
|
Blotting, Southern | 1 | 2000 | 780 | 0.040 |
Why?
|
Fibrinolytic Agents | 1 | 2009 | 2084 | 0.040 |
Why?
|
Palliative Care | 1 | 2014 | 3600 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2006 | 2423 | 0.040 |
Why?
|
Choroid Plexus Neoplasms | 1 | 1999 | 38 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2006 | 2898 | 0.040 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2003 | 646 | 0.040 |
Why?
|
Drug Approval | 2 | 2018 | 814 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2022 | 328 | 0.040 |
Why?
|
DNA Probes | 1 | 2000 | 544 | 0.040 |
Why?
|
Substrate Specificity | 2 | 2015 | 1791 | 0.040 |
Why?
|
Affect | 1 | 2007 | 1485 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 2851 | 0.040 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2000 | 313 | 0.040 |
Why?
|
Receptor, TIE-2 | 1 | 2019 | 176 | 0.040 |
Why?
|
PTEN Phosphohydrolase | 2 | 2015 | 1115 | 0.040 |
Why?
|
Motor Activity | 1 | 2009 | 2711 | 0.040 |
Why?
|
Edema | 1 | 2023 | 767 | 0.040 |
Why?
|
Observer Variation | 2 | 2015 | 2605 | 0.040 |
Why?
|
Wound Healing | 1 | 2010 | 2803 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2018 | 12058 | 0.040 |
Why?
|
Propensity Score | 2 | 2017 | 1908 | 0.040 |
Why?
|
Risk Factors | 5 | 2018 | 74167 | 0.040 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2000 | 418 | 0.040 |
Why?
|
Craniotomy | 2 | 2015 | 741 | 0.040 |
Why?
|
Vincristine | 3 | 2013 | 1036 | 0.040 |
Why?
|
Immunization | 1 | 2023 | 1227 | 0.040 |
Why?
|
Hybrid Cells | 1 | 1998 | 422 | 0.040 |
Why?
|
Models, Molecular | 1 | 2008 | 5439 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 243 | 0.040 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2018 | 145 | 0.040 |
Why?
|
Fluorouracil | 1 | 2003 | 1639 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1994 | 3613 | 0.040 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 1999 | 346 | 0.040 |
Why?
|
Tumor Escape | 1 | 2021 | 370 | 0.040 |
Why?
|
Single-Chain Antibodies | 1 | 2018 | 111 | 0.040 |
Why?
|
Gene Order | 1 | 2018 | 169 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 785 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 15941 | 0.040 |
Why?
|
Protein Kinases | 1 | 2005 | 1607 | 0.040 |
Why?
|
Procarbazine | 2 | 2013 | 172 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2021 | 584 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2013 | 14599 | 0.040 |
Why?
|
Adaptive Immunity | 1 | 2022 | 725 | 0.040 |
Why?
|
Killer Cells, Natural | 2 | 2021 | 2203 | 0.040 |
Why?
|
Remission Induction | 1 | 2023 | 2395 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2019 | 233 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 247 | 0.040 |
Why?
|
Cell Division | 1 | 2005 | 4466 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 1036 | 0.040 |
Why?
|
North Carolina | 2 | 2011 | 325 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 246 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1999 | 535 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2009 | 26112 | 0.030 |
Why?
|
DNA Mismatch Repair | 1 | 2020 | 428 | 0.030 |
Why?
|
Janus Kinase 2 | 1 | 2020 | 560 | 0.030 |
Why?
|
Lymphocytic choriomeningitis virus | 1 | 2018 | 177 | 0.030 |
Why?
|
Software | 2 | 2010 | 4434 | 0.030 |
Why?
|
Genotype | 3 | 2016 | 13009 | 0.030 |
Why?
|
Radiotherapy | 2 | 2016 | 1499 | 0.030 |
Why?
|
Guidelines as Topic | 2 | 2016 | 1385 | 0.030 |
Why?
|
Antigens | 1 | 2022 | 1446 | 0.030 |
Why?
|
Hypertension | 2 | 2015 | 8542 | 0.030 |
Why?
|
Genomics | 2 | 2024 | 5820 | 0.030 |
Why?
|
Receptors, Virus | 1 | 2020 | 640 | 0.030 |
Why?
|
Interferons | 1 | 2020 | 705 | 0.030 |
Why?
|
Proteins | 1 | 2011 | 6032 | 0.030 |
Why?
|
Steroids | 1 | 2021 | 929 | 0.030 |
Why?
|
Cerebrospinal Fluid | 1 | 1999 | 544 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 2010 | 2892 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 558 | 0.030 |
Why?
|
Protein Binding | 1 | 2008 | 9352 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1232 | 0.030 |
Why?
|
Injections, Intravenous | 2 | 2010 | 1380 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1827 | 0.030 |
Why?
|
Blotting, Western | 3 | 2015 | 5036 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 615 | 0.030 |
Why?
|
Phenotype | 3 | 2020 | 16606 | 0.030 |
Why?
|
Placebos | 1 | 2020 | 1667 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12688 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2015 | 9606 | 0.030 |
Why?
|
X Chromosome | 1 | 1999 | 816 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2328 | 0.030 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5794 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2008 | 4063 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2000 | 1834 | 0.030 |
Why?
|
Hospitalization | 1 | 2015 | 10718 | 0.030 |
Why?
|
Leukopenia | 1 | 2015 | 213 | 0.030 |
Why?
|
Awareness | 1 | 2019 | 647 | 0.030 |
Why?
|
Membrane Glycoproteins | 1 | 2006 | 3702 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1613 | 0.030 |
Why?
|
Sensitivity and Specificity | 4 | 2020 | 14664 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2019 | 871 | 0.030 |
Why?
|
Frozen Sections | 1 | 2015 | 153 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2003 | 1600 | 0.030 |
Why?
|
Receptors, Interferon | 1 | 1995 | 116 | 0.030 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2015 | 411 | 0.030 |
Why?
|
Tumor Cells, Cultured | 4 | 2009 | 6132 | 0.030 |
Why?
|
Life Style | 1 | 2006 | 3914 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2015 | 511 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2015 | 241 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2015 | 416 | 0.030 |
Why?
|
Pons | 1 | 2015 | 240 | 0.030 |
Why?
|
Immunization, Passive | 2 | 2008 | 616 | 0.030 |
Why?
|
Bone Marrow | 1 | 2024 | 2910 | 0.030 |
Why?
|
RNA, Messenger | 3 | 2016 | 12796 | 0.030 |
Why?
|
Epitopes | 2 | 2018 | 2507 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2018 | 2469 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4575 | 0.030 |
Why?
|
Retreatment | 1 | 2015 | 598 | 0.030 |
Why?
|
Receptors, Somatostatin | 1 | 2014 | 136 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2001 | 1085 | 0.030 |
Why?
|
Antibodies | 1 | 2002 | 2421 | 0.030 |
Why?
|
Viral Matrix Proteins | 1 | 2015 | 196 | 0.030 |
Why?
|
Health Status | 1 | 2007 | 4075 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2017 | 2914 | 0.030 |
Why?
|
Paclitaxel | 1 | 2001 | 1732 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2006 | 3460 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2015 | 350 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1150 | 0.030 |
Why?
|
Travel | 1 | 2019 | 796 | 0.030 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2016 | 2790 | 0.030 |
Why?
|
Drug Antagonism | 1 | 2013 | 51 | 0.030 |
Why?
|
Selection Bias | 1 | 2015 | 359 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2019 | 9535 | 0.030 |
Why?
|
Standard of Care | 1 | 2017 | 550 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3647 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2019 | 3597 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2015 | 603 | 0.030 |
Why?
|
Immune Tolerance | 1 | 2022 | 2300 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 1806 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2001 | 5670 | 0.030 |
Why?
|
Microglia | 1 | 2021 | 1361 | 0.030 |
Why?
|
Nausea | 1 | 2015 | 679 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3447 | 0.030 |
Why?
|
Abortion Applicants | 1 | 1992 | 5 | 0.030 |
Why?
|
Exercise Test | 2 | 2011 | 2129 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4741 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2015 | 916 | 0.030 |
Why?
|
Phosphorylation | 2 | 2018 | 8320 | 0.020 |
Why?
|
Serum Albumin, Radio-Iodinated | 1 | 2011 | 37 | 0.020 |
Why?
|
Breast Neoplasms | 4 | 2013 | 21012 | 0.020 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 1994 | 431 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4354 | 0.020 |
Why?
|
Educational Status | 1 | 2019 | 2520 | 0.020 |
Why?
|
Blood Component Transfusion | 1 | 1992 | 142 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 898 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2019 | 1265 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 946 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1218 | 0.020 |
Why?
|
Cyclophosphamide | 3 | 2003 | 2218 | 0.020 |
Why?
|
Y Chromosome | 1 | 1992 | 205 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1363 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3423 | 0.020 |
Why?
|
Constipation | 1 | 2015 | 562 | 0.020 |
Why?
|
Optic Chiasm | 1 | 2011 | 91 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2015 | 4370 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2000 | 7856 | 0.020 |
Why?
|
Injections, Intradermal | 1 | 2010 | 116 | 0.020 |
Why?
|
Computer Simulation | 1 | 2024 | 6238 | 0.020 |
Why?
|
Transcription Factors | 2 | 2024 | 12125 | 0.020 |
Why?
|
Methods | 1 | 2011 | 1074 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1347 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3580 | 0.020 |
Why?
|
Melphalan | 2 | 2003 | 420 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1469 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 2013 | 656 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2013 | 718 | 0.020 |
Why?
|
SEER Program | 1 | 2015 | 1450 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1998 | 1378 | 0.020 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2015 | 727 | 0.020 |
Why?
|
Pregnancy in Adolescence | 1 | 1992 | 163 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2523 | 0.020 |
Why?
|
Scotoma | 1 | 2011 | 130 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2010 | 2010 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 774 | 0.020 |
Why?
|
Hypersensitivity, Delayed | 1 | 2010 | 490 | 0.020 |
Why?
|
Genes, erbB-1 | 1 | 2010 | 162 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1999 | 2824 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2012 | 4549 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2449 | 0.020 |
Why?
|
Epidermal Growth Factor | 2 | 2003 | 701 | 0.020 |
Why?
|
Carcinoma | 1 | 2001 | 2330 | 0.020 |
Why?
|
United States | 4 | 2018 | 72339 | 0.020 |
Why?
|
Cognition | 1 | 2007 | 6986 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 694 | 0.020 |
Why?
|
Multiple Sclerosis | 1 | 2024 | 3224 | 0.020 |
Why?
|
Genetic Markers | 1 | 2015 | 2613 | 0.020 |
Why?
|
Colorectal Neoplasms | 2 | 2013 | 6935 | 0.020 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1991 | 226 | 0.020 |
Why?
|
Gene Silencing | 1 | 2015 | 1509 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 2010 | 287 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2012 | 2016 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1858 | 0.020 |
Why?
|
Visual Field Tests | 1 | 2011 | 411 | 0.020 |
Why?
|
Base Sequence | 3 | 1995 | 12450 | 0.020 |
Why?
|
Models, Statistical | 1 | 2023 | 5077 | 0.020 |
Why?
|
Tomography, Emission-Computed | 1 | 2011 | 1122 | 0.020 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2008 | 106 | 0.020 |
Why?
|
Multiple Organ Failure | 1 | 1991 | 387 | 0.020 |
Why?
|
Transcobalamins | 1 | 2007 | 19 | 0.020 |
Why?
|
Carotenoids | 1 | 2011 | 621 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2011 | 540 | 0.020 |
Why?
|
Platelet Count | 1 | 1990 | 782 | 0.020 |
Why?
|
Alpha Particles | 1 | 2007 | 29 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2013 | 823 | 0.020 |
Why?
|
Cerebellum | 1 | 2015 | 1500 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2018 | 10441 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2015 | 1695 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2010 | 15650 | 0.020 |
Why?
|
Sample Size | 1 | 2010 | 840 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 3798 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2016 | 2455 | 0.020 |
Why?
|
Genome, Human | 1 | 2020 | 4425 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2014 | 1931 | 0.020 |
Why?
|
Vitamin E | 1 | 2011 | 872 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 1995 | 17644 | 0.020 |
Why?
|
Infusions, Intra-Arterial | 1 | 2007 | 222 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7825 | 0.020 |
Why?
|
Thymidine | 1 | 2006 | 299 | 0.020 |
Why?
|
Vaccines, DNA | 1 | 2008 | 286 | 0.020 |
Why?
|
Immune System | 1 | 2012 | 795 | 0.020 |
Why?
|
Stroke | 1 | 2008 | 9756 | 0.020 |
Why?
|
Receptors, Growth Factor | 1 | 2007 | 326 | 0.020 |
Why?
|
Radioisotopes | 1 | 2007 | 499 | 0.020 |
Why?
|
Megakaryocytes | 1 | 1990 | 566 | 0.020 |
Why?
|
Isotope Labeling | 1 | 2007 | 393 | 0.020 |
Why?
|
Pseudomonas aeruginosa | 2 | 2005 | 1277 | 0.020 |
Why?
|
Antigen-Antibody Reactions | 1 | 2006 | 346 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2015 | 2448 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2012 | 1989 | 0.020 |
Why?
|
Drug Combinations | 1 | 2011 | 2048 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17912 | 0.010 |
Why?
|
Computational Biology | 1 | 2016 | 3517 | 0.010 |
Why?
|
Skin | 1 | 2018 | 4481 | 0.010 |
Why?
|
Drug Administration Routes | 1 | 2004 | 150 | 0.010 |
Why?
|
Cytokines | 1 | 2019 | 7392 | 0.010 |
Why?
|
Databases, Factual | 1 | 2020 | 7956 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 473 | 0.010 |
Why?
|
Leukocytes | 1 | 1992 | 2028 | 0.010 |
Why?
|
Visual Fields | 1 | 2011 | 1062 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 477 | 0.010 |
Why?
|
Models, Biological | 2 | 2013 | 9469 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 1991 | 1793 | 0.010 |
Why?
|
Gangliosides | 1 | 2004 | 132 | 0.010 |
Why?
|
Fluorine Radioisotopes | 1 | 2006 | 418 | 0.010 |
Why?
|
Counseling | 1 | 1992 | 1546 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3357 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2007 | 1496 | 0.010 |
Why?
|
Vision Disorders | 1 | 2011 | 1088 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 2005 | 442 | 0.010 |
Why?
|
Capillary Permeability | 1 | 2007 | 774 | 0.010 |
Why?
|
Infusions, Parenteral | 1 | 2003 | 398 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3810 | 0.010 |
Why?
|
Loss of Heterozygosity | 1 | 2005 | 662 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1068 | 0.010 |
Why?
|
MicroRNAs | 1 | 2019 | 3812 | 0.010 |
Why?
|
Doxorubicin | 2 | 2001 | 2224 | 0.010 |
Why?
|
Incidence | 2 | 2015 | 21341 | 0.010 |
Why?
|
Staining and Labeling | 1 | 2007 | 1084 | 0.010 |
Why?
|
Nitrosourea Compounds | 1 | 2002 | 32 | 0.010 |
Why?
|
Corpus Callosum | 1 | 2007 | 751 | 0.010 |
Why?
|
Necrosis | 1 | 2007 | 1608 | 0.010 |
Why?
|
Anticoagulants | 1 | 2018 | 4813 | 0.010 |
Why?
|
Busulfan | 1 | 2003 | 258 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2004 | 1060 | 0.010 |
Why?
|
Reoperation | 2 | 2005 | 4303 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6966 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2005 | 1900 | 0.010 |
Why?
|
Tyrphostins | 1 | 2001 | 63 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2019 | 11902 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2010 | 2161 | 0.010 |
Why?
|
Alternative Splicing | 1 | 2006 | 1093 | 0.010 |
Why?
|
Neuregulin-1 | 1 | 2001 | 135 | 0.010 |
Why?
|
Drug Resistance, Viral | 1 | 2005 | 861 | 0.010 |
Why?
|
Functional Laterality | 1 | 2007 | 2256 | 0.010 |
Why?
|
Autocrine Communication | 1 | 2001 | 169 | 0.010 |
Why?
|
Benzothiazoles | 1 | 2001 | 247 | 0.010 |
Why?
|
Receptor, erbB-3 | 1 | 2001 | 143 | 0.010 |
Why?
|
Life Tables | 1 | 2000 | 365 | 0.010 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1651 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 3201 | 0.010 |
Why?
|
HeLa Cells | 1 | 2006 | 3093 | 0.010 |
Why?
|
Pedigree | 1 | 2007 | 4589 | 0.010 |
Why?
|
Colon | 1 | 2007 | 1792 | 0.010 |
Why?
|
Astrocytes | 1 | 2007 | 1345 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4172 | 0.010 |
Why?
|
Growth Substances | 1 | 2001 | 768 | 0.010 |
Why?
|
Genetic Engineering | 1 | 2004 | 933 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1998 | 129 | 0.010 |
Why?
|
Kinetics | 1 | 2006 | 6374 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2003 | 2116 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2010 | 2529 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2001 | 629 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 1991 | 3030 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2018 | 26212 | 0.010 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 1999 | 188 | 0.010 |
Why?
|
DNA Replication | 1 | 2005 | 1418 | 0.010 |
Why?
|
Lumbosacral Region | 1 | 1999 | 293 | 0.010 |
Why?
|
Tomography, Optical Coherence | 1 | 2011 | 2917 | 0.010 |
Why?
|
Growth Hormone | 1 | 1999 | 569 | 0.010 |
Why?
|
Bleomycin | 1 | 1998 | 494 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1999 | 1626 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2007 | 2727 | 0.010 |
Why?
|
Choroid Plexus | 1 | 1999 | 240 | 0.010 |
Why?
|
Vinblastine | 1 | 1998 | 488 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2005 | 2386 | 0.010 |
Why?
|
Survivors | 1 | 2007 | 2371 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6532 | 0.010 |
Why?
|
Stress, Psychological | 1 | 1992 | 4477 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2011 | 18964 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2009 | 2566 | 0.010 |
Why?
|
Tamoxifen | 1 | 2000 | 965 | 0.010 |
Why?
|
Protein Kinase C | 1 | 2000 | 1202 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2001 | 710 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2013 | 5365 | 0.010 |
Why?
|
Carbohydrate Conformation | 1 | 1995 | 206 | 0.010 |
Why?
|
Cisplatin | 1 | 2001 | 1650 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 5302 | 0.010 |
Why?
|
Prednisone | 1 | 1998 | 1562 | 0.010 |
Why?
|
Molecular Weight | 1 | 1995 | 2188 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2006 | 7595 | 0.010 |
Why?
|
Glycosylation | 1 | 1995 | 1098 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2004 | 4414 | 0.010 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1992 | 779 | 0.010 |
Why?
|
Blood Donors | 1 | 1992 | 345 | 0.010 |
Why?
|
Graft Survival | 1 | 2001 | 3819 | 0.010 |
Why?
|
Pregnancy | 1 | 1992 | 29862 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2009 | 20556 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1995 | 13449 | 0.000 |
Why?
|
Liver Transplantation | 1 | 1992 | 2333 | 0.000 |
Why?
|
DNA | 1 | 1992 | 7219 | 0.000 |
Why?
|
Cardiac Surgical Procedures | 1 | 1992 | 3630 | 0.000 |
Why?
|